Incyte (INCY) Non Operating Investment Income (2015 - 2026)
Incyte (INCY) posted Non Operating Investment Income of $6.6 million for Q1 2026, down 63.88% on a QoQ basis from $18.2 million in Q4 2025, and up 590.77% year-over-year from $954156.8 in Q1 2025.
Incyte (INCY) Non Operating Investment Income (2015 - 2026) Analysis & Trends
Incyte's Non Operating Investment Income history runs 7 years deep, the most recent figure standing at $6.6 million for Q1 2026.
- Quarterly Non Operating Investment Income rose 590.77% year-over-year to $6.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $29.2 million (up 98.47% YoY) and the FY2025 annual result came in at $21.3 million, down 81.63% from the prior year.
- Non Operating Investment Income was $6.6 million for Q1 2026 at Incyte, down from $18.2 million in the prior quarter.
- Across five years, Non Operating Investment Income topped out at $99.9 million in Q1 2024 and bottomed at -$26.7 million in Q3 2023.
- A 4-year average of $16.1 million and a median of $7.6 million in 2025 frame the typical range for Non Operating Investment Income.
- Annual changes were most pronounced in 2024 — Non Operating Investment Income slumped 129.9% — and 2026, when it jumped 590.77%.
- Incyte's Non Operating Investment Income stood at $34.1 million in 2023, then slumped by 129.9% to -$10.2 million in 2024, then jumped by 279.22% to $18.2 million in 2025, then slumped by 63.88% to $6.6 million in 2026.
- Business Quant data shows INCY's Non Operating Investment Income at $6.6 million in Q1 2026, $18.2 million in Q4 2025, and $8.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Incyte | 23.64 Bn | 19.62 Bn | 1.17 Bn | 6.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.59 Mn |
| Mar 31, 2026 | 6.59 Mn |
| Dec 31, 2025 | 18.25 Mn |
| Dec 31, 2025 | 18.25 Mn |
| Sep 30, 2025 | 8.56 Mn |
| Sep 30, 2025 | 8.56 Mn |
| Jun 30, 2025 | -4.15 Mn |
| Jun 30, 2025 | -4.15 Mn |
| Mar 31, 2025 | -1.34 Mn |
| Mar 31, 2025 | -1.34 Mn |
| Dec 31, 2024 | -10.18 Mn |
| Dec 31, 2024 | -10.18 Mn |
| Sep 30, 2024 | -12.98 Mn |
| Sep 30, 2024 | -12.98 Mn |
| Jun 30, 2024 | 39.24 Mn |
| Jun 30, 2024 | 39.24 Mn |
| Mar 31, 2024 | 99.95 Mn |
| Mar 31, 2024 | 99.95 Mn |
| Dec 31, 2023 | 34.05 Mn |
| Dec 31, 2023 | 34.05 Mn |